RESEARCH ARTICLE

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis

Elmira Agah1,2, Arshia Zardoui1,2*, Amene Saghazadeh3,4*, Mona Ahmadi5, Abbas Tafakhori2,5*, Nima Rezaei3,6*

1 Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran, 2 NeuroImmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran, 3 Research Center for Immunodeficiencies (RCID), Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran, 4 Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Boston, MA, United States of America, 5 Iranian Center of Neurological Research (ICNR), Tehran University of Medical Sciences, Tehran, Iran, 6 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

☯ These authors contributed equally to this work.
* a_tafakhori@sina.tums.ac.ir (AT); rezaei_nima@tums.ac.ir (NR)

Abstract

Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid (CSF) and peripheral blood concentration of osteopontin (OPN) may have diagnostic and prognostic value in MS. We conducted a systematic review and meta-analysis of studies that measured peripheral blood and CSF levels of OPN in MS patients and controls to evaluate the diagnostic potential of this biomarker better. We searched PubMed, Web of Science and Scopus databases to find articles that measured OPN concentration in peripheral blood and CSF samples from MS patients up to October 19, 2016. Q statistic tests and the I2 index were applied for heterogeneity assessment. If the I2 index was less than 40%, the fixed-effects model was used for meta-analysis. Random-effects meta-analysis was chosen if the I2 value was greater than 40%. After removal of duplicates, 918 articles were identified, and 27 of them fulfilled the inclusion criteria. We included 22 eligible studies in the final meta-analysis. MS patients, in general, had considerably higher levels of OPN in their CSF and blood when compared to all types of controls (p < 0.05). When the comparisons were made between different subtypes of MS patients and controls, the results pointed to significantly higher levels of OPN in CSF of MS subgroups (p < 0.05). All subtypes of MS patients, except CIS patients, had increased blood levels of OPN compared to controls (p < 0.05). In the second set of meta-analyses, we compared the peripheral blood and CSF concentrations of OPN between MS patient subtypes. CIS patients had significantly lower levels of OPN both in their peripheral blood and CSF compared to patients with progressive subtypes of MS (p < 0.05). CSF concentration of OPN was significantly higher among RRMS patients compared to the CIS patients and SPMS patients (P < 0.05). Finally, patients with active MS had significantly higher OPN levels in their CSF compared to patients with stable disease (P = 0.007). The result of this study confirms that increased levels of OPN exist in
CSF and peripheral blood of MS patients and strengthens the evidence regarding the clinical utility of OPN as a promising and validated biomarker for MS.

Introduction

Multiple sclerosis is a chronic, progressive, immune-mediated central nervous system (CNS) disorder characterized by inflammation, demyelination and axonal damage leading to neurodegeneration [1]. MS affects more than 2.5 million people worldwide [2], and is a leading cause of disability in young adults. According to their clinical course, MS patients are categorized into four major subtypes: (1) clinically isolated syndrome (CIS); an initial presentation of MS, (2) relapsing-remitting MS (RRMS); the most common type of MS, (3) primary progressive MS (PPMS); clinically progressive disease without any recovery, and (4) secondary progressive MS (SPMS); which usually develops after years of relapsing-remitting disease [3].

The heavy burden of disease necessitates early diagnosis and management of MS [4]. However, correct diagnosis of MS may be challenging, especially during the initial stages in which individuals may present with more non-specific complaints and imaging signs [5]. According to the McDonald diagnostic criteria, for true differentiation of MS from other alternative diagnoses, patient brain lesions need to fulfill the dissemination in time and space conditions [6]. Although brain magnetic resonance imaging (MRI) has a critical role in the diagnosis of MS [7], overlap between MRI findings of MS and other neurological disorders makes a definite diagnosis of MS difficult [8]. Evaluation of the cerebrospinal fluid (CSF) and evoked potential (EP) studies might be helpful in these cases [9, 10]. EPs are less sensitive than MRI but may be beneficial for diagnosing MS in subclinical cases [10]. Analysis of CSF for immunoglobulin G (IgG) index and oligoclonal bands (OCBs) can provide diagnostic aid in suspected cases of MS [6, 9]. However, lumbar puncture (LP), which is used to collect CSF, is an invasive procedure that might limit the applicability of these tests. Since blood collection is a less invasive procedure, finding a reliable blood-borne biomarker for MS is urgently needed [5, 11, 12].

Biomarkers are objective indicators of underlying pathology [13]; and they could be applied for diagnostic, prognostic and therapeutic aims in the clinical setting [11, 12, 14]. A variety of molecular biomarkers have been proposed for MS; however, a minority of them have been employed in clinical practice [12]. Based on evidence strength, proposed biomarkers for MS are categorized into exploratory or potential biomarkers, validated biomarkers, and clinically useful biomarkers [11]. The category of validated biomarkers has good potential to become clinically useful. To achieve this goal, critical evaluation of existing evidence is needed. Currently, this category of biomarkers is mostly composed of inflammatory biomarkers such as interleukin 17 (IL-17), the tumor necrosis factor (TNF) superfamily, and osteopontin (OPN) [11, 12, 15].

OPN is an extracellular matrix protein involved in a variety of physiologic functions and pathological states such as bone remodeling, wound healing, cancer biology, vascular disorders, and inflammatory diseases [15, 16]. OPN is widely expressed in immune cells, including T cells, dendritic cells, macrophages, and natural killer cells and contributes to inflammation via increasing production of IL-12, IL-17 and interferon gamma (IFN-γ) and inhibiting expression of IL-10 [17]. Therefore, its potential role in pathology of MS as an autoimmune disorder has frequently been investigated [18–20]. The OPN gene expression was found to be increased in MS brain lesions [21]. Different studies have found that the variant of OPN gene
has a significant impact on risk of developing MS, the disease course, and serum OPN levels [22, 23]. Also, some other studies in both humans and animals have linked the OPN levels to disease progression and recurrent relapses [19, 24]. Therefore, OPN may be a good disease biomarker for MS. Thus far, altered levels of OPN in blood and CSF of MS patients have been suggested by many studies and majority report increased concentrations of OPN in patients with MS [20, 22, 25–49]. However, as disease controls, changes in OPN level in other inflammatory and non-inflammatory conditions have also been observed. So, there is a need to appraise and systematically review the existing literature.

To the best of our knowledge, this study is the first systematic review and meta-analysis of studies that have measured peripheral blood and CSF levels of OPN in MS patients and controls. The aim of the present meta-analysis is to evaluate the potential of OPN as a diagnostic biomarker for MS.

**Materials and methods**

**Search strategy and study selection**

This paper was written according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (S1 File) [50]. The protocol of this systematic review and meta-analysis was registered in the PROSPERO website (https://www.crd.york.ac.uk/PROSPERO/) with registration number CRD42016043050.

We searched PubMed, Web of Science and Scopus databases to find related articles up to October 19, 2016. Combination of the following terms was used to identify eligible studies: ("Osteopontin" OR "OPN" OR "Bone sialoprotein I" OR "BSP-1" OR "BSP 1" OR "BSP1" OR "BSPI" OR "BNSP" OR "Early T-lymphocyte activation" OR "ETA-1" OR "ETA 1" OR "ETAI" OR "ETAI" OR "Secreted phosphoprotein 1" OR "SPP-1" OR "SPP 1" OR "SPP1" OR "SPP1" OR "Rickettsia resistance" OR "Ric" AND (Multiple sclerosis OR MS OR Disseminated sclerosis OR Encephalomyelitis disseminata). A detailed search strategy is provided in S1 Appendix. Reference lists of the relevant articles were searched manually to identify additional related studies. All literature searches were performed by two authors independently (EA and AS) and no language or publication date restriction was applied.

Original articles were considered eligible to be included if: (1) they were observational studies or reported the baseline phase of randomized clinical trials (RCTs) which measured OPN in CSF or blood samples of human subjects diagnosed with MS; (2) sufficient data (at least number of patients and study controls as well as the OPN numerical measurement results) were provided. Studies were not considered if no comparison group existed or if any history of concomitant disease or any drug use, which may affect the concentration of OPN, was noted.

**Quality assessment and data extraction**

Two of our authors (EA and AZ) extracted the following data from each study individually: First author’s name, year of publication, country, sample type (CSF or peripheral blood), number of participants, age, sex ratio, duration of disease (year), MS subtype, type of control group, MS phase at time of sampling (active/stable or relapse/remission), treatment status at sampling (treated or untreated) and OPN levels. Third author’s (AS or AT) opinion was sought for any inconsistency found among the data extracted.

For quality appraisal of included studies, Newcastle–Ottawa Scale (NOS) for nonrandomized studies was used.[51] This tool evaluates the risk of bias by assessing the quality of sample selection, comparability of cases and controls and the outcome ascertainment method. Then, studies are judged as high-quality (with a score range of 7–9), medium-quality (scores of 4–6) or low-quality (scores less than 4) based on the scores obtained (possible range: 0–9).
In all meta-analyses, MS patients (CIS, RRMS, SPMS, PPMS or unspecified) were included as the disease group. To better compare the cases and controls, control subjects were further categorized as; healthy controls (HCs), non-inflammatory neurological disorder (NIND) controls, and inflammatory neurological disorder (IND) controls.

**Statistical analysis**

All meta-analyses were performed by using the STATA version 14.0. Mean and standard deviation (SD) of OPN concentrations and the number of participants were also entered for each group. Regarding the studies which reported the median and range/inter-quartile range of OPN, mean SD was estimated if the sample size was reported; otherwise, it was excluded. Q statistic tests and the I² index were applied for heterogeneity assessment. The I² index was interpreted according to the Cochrane handbook [52]. If the I² index was less than 40%, the heterogeneity was considered not important; therefore, fixed-effects model was used for meta-analysis. Random-effects meta-analysis was chosen if the I² value was greater than 40%. Standardized mean difference (SMD) and 95% confidence interval (CI) were used for effect measurement. Publication bias was evaluated by funnel plot and Egger test if more than 4 studies were included in the meta-analysis [53]. In this study, p values ≤ 0.05 are considered significant.

**Results**

Our search strategy identified 1,409 articles initially, and, after removal of duplicates, 918 articles remained. The remaining articles were assessed for eligibility, and 27 of them fulfilled the inclusion criteria. We later searched 98 pages of Google Scholar to find additional articles, but no paper was added. Finally, 22 studies were included in the meta-analysis (five studies were excluded due to not reporting sufficient data) (Fig 1). Characteristics of the included studies are shown in the S1 Table. The results of quality assessment showed a medium quality for eight articles and high quality for rest of the studies included in the meta-analysis (Table 1).

First, we conducted a set of meta-analyses to find the difference between MS patients and controls regarding both peripheral blood (plasma or serum) and CSF concentration of OPN (a full summary of results is shown in Tables 2 and 3). MS patients, in general, had a considerably higher level of OPN in their CSF compared to all types of controls (p < 0.01, Fig 2 (A)). When the comparisons were made between different subtypes of MS patients and controls, the results pointed to significantly higher levels of OPN in CSF of MS subgroups (Fig 2). Blood concentrations of OPN were also significantly higher in MS patients (p < 0.05), however, Q statistic results revealed a considerable heterogeneity among the studies which measured the OPN level in peripheral blood (more than 90%). We realized that one of the included studies [25], is a major source of heterogeneity, so we omitted it from all meta-analyses with I² index > 75% to get more reliable results. All subtypes of MS patients except CIS patients had increased blood levels of OPN compared to the HCs and/or NIND patients (p < 0.05, Fig 3).

In the second set of meta-analyses, we compared the peripheral blood and CSF concentration of OPN between subtypes of MS patients. CIS patients had significantly lower levels of OPN both in their peripheral blood and CSF in comparison to the PPMS patients (Fig 4). CSF concentration of OPN was significantly higher among RRMS patients compared to the CIS patients and SPMS patients (p < 0.05, Fig 4). Finally, patients with active MS had significantly higher OPN levels in their CSF compared to patients with stable disease (P = 0.007, Fig 4). The OPN levels did not differ significantly among the other subtypes of MS patients either in CSF or peripheral blood (p > 0.05).
As is demonstrated in Tables 2 and 3, heterogeneity was found in majority of meta-analyses; therefore, meta-analysis with a random effects model was applied to the study. Publication bias was evaluated by Egger’s test and funnel plot (S2 and S3 Files), which pointed to no significant bias for most of the meta-analyses except the bold ones in Tables 2 and 3.
Here we present a systematic review and meta-analysis of OPN concentration in MS patients’ peripheral blood and CSF samples for the first time. The results of this study indicate that both peripheral blood and CSF levels of this biomarker are increased among MS patients. Although CSF samples are more sensitive for detecting biomarker levels in MS, blood biomarkers are preferred because they are collected more easily by a less invasive procedure. Therefore, significantly higher levels of OPN in peripheral blood of MS patients compared to controls could be an interesting finding of the present study which emphasizes the clinical applicability of this biomarker even more.

Finding higher levels of OPN in samples from MS patients is in agreement with the T cell mediated nature of the disease [54]. OPN is highly expressed in activated T cells and can modulate the activation pathway by cytokine regulation [16]. Ex vivo studies on T cells from both experimental autoimmune encephalomyelitis (EAE) models and MS patients indicate an increase in the number of OPN receptors on these cells [55]. It was shown that in the presence of human OPN, purified CD4+ T cells from MS patients exert more inflammatory responses compared with healthy controls [55]. Moreover, Braitch et al. reported that OPN levels were positively correlated with the relative presence of Th1 cytokine, IL12p40, in the CSF of patients with MS [28]. Chabas et al. suggested that OPN may have an important role in MS pathology by Th1 response regulation; they showed that while production of IL-10 was increased in OPN/−/− mice, INF-γ and IL-12 productions were diminished compared to OPN+/+ ones [21]. Cell survival maintenance is another feature of OPN that may contribute to its role in autoimmune diseases such as MS [16, 56, 57]. It was demonstrated that injecting recombinant OPN to OPN/−/− mice reversed the remission phase of EAE and led to disease progression which was

### Table 1. Quality assessment of the included studies.

| Study             | Selection | Comparability | Exposure | Score |
|-------------------|-----------|---------------|----------|-------|
| Vogt 2003         | *         | *             | *        | 7     |
| Chiocchetti 2005  | *         | *             | *        | 8     |
| Chowdhury 2008    | *         | *             | *        | 6     |
| Braitch 2008      |           | *             | *        | 5     |
| Khademi 2009      | *         | *             | *        | 7     |
| Altintas 2009     | *         | *             | *        | 7     |
| Vogt 2010         | *         | *             | *        | 8     |
| Bornsen 2011      |           | *             | *        | 6     |
| Assadi 2011       | *         | *             | *        | 9     |
| Wen 2012          | *         | *             | *        | 7     |
| Romme Christensen 2013 | *   | *             | *        | 7     |
| Szalardy 2013     |           | *             | *        | 7     |
| Shimizu 2013      |           | *             | *        | 5     |
| Iaffaldano 2013   |           | *             | *        | 6     |
| Edwards 2013      |           | *             | *        | 7     |
| Khademi 2013      | *         | *             | *        | 9     |
| Kiviäk 2104       | *         | *             | *        | 8     |
| Ma 2014           |           | *             | *        | 5     |
| Stilund 2015      | *         | *             | *        | 8     |
| Kariya 2015       |           | *             | *        | 6     |
| Strehlov 2016     |           | *             | *        | 6     |
| Ferret-Sena 2016  | *         | *             | *        | 8     |

https://doi.org/10.1371/journal.pone.0190252.t001

### Discussion

Here we present a systematic review and meta-analysis of OPN concentration in MS patients’ peripheral blood and CSF samples for the first time. The results of this study indicate that both peripheral blood and CSF levels of this biomarker are increased among MS patients. Although CSF samples are more sensitive for detecting biomarker levels in MS, blood biomarkers are preferred because they are collected more easily by a less invasive procedure. Therefore, significantly higher levels of OPN in peripheral blood of MS patients compared to controls could be an interesting finding of the present study which emphasizes the clinical applicability of this biomarker even more.

Finding higher levels of OPN in samples from MS patients is in agreement with the T cell mediated nature of the disease [54]. OPN is highly expressed in activated T cells and can modulate the activation pathway by cytokine regulation [16]. Ex vivo studies on T cells from both experimental autoimmune encephalomyelitis (EAE) models and MS patients indicate an increase in the number of OPN receptors on these cells [55]. It was shown that in the presence of human OPN, purified CD4+ T cells from MS patients exert more inflammatory responses compared with healthy controls [55]. Moreover, Braitch et al. reported that OPN levels were positively correlated with the relative presence of Th1 cytokine, IL12p40, in the CSF of patients with MS [28]. Chabas et al. suggested that OPN may have an important role in MS pathology by Th1 response regulation; they showed that while production of IL-10 was increased in OPN−/− mice, INF-γ and IL-12 productions were diminished compared to OPN+/+ ones [21]. Cell survival maintenance is another feature of OPN that may contribute to its role in autoimmune diseases such as MS [16, 56, 57]. It was demonstrated that injecting recombinant OPN to OPN−/− mice reversed the remission phase of EAE and led to disease progression which was
Table 2. Summary of meta-analyses undertaken in studies which measured CSF levels of OPN.

| Specimen | Group I | Group II | No of comparisons | No of group 1/ group 2 | Heterogeneity (χ², P) | Inconsistency | Effect measure (95% CI) | Overall effect (p value) | Egger’s test | References |
|----------|---------|----------|-------------------|-----------------------|----------------------|---------------|------------------------|----------------------|-------------|------------|
| CSF      | MS      | IND      | 4                 | 715/248               | (χ² = 8.22, P = 0.042) | I² = 63.5%     | SMD = -0.476 (-1.007–0.555) | Z = 1.76 P = 0.079 | N/A         | [28, 32, 37, 45] |
| CSF      | MS      | NIND     | 9                 | 1032/414              | (χ² = 79.47, P < 0.001) | I² = 89.9%     | SMD = 1.137 (0.661–1.613) | Z = 4.68 P < 0.001 | T = 2.30 P = 0.055 | [27, 28, 32, 36, 37, 41, 45, 46, 49] |
| CSF      | MS      | NIND and HC | 10               | 1118/466             | (χ² = 78.80, P < 0.001) | I² = 89.5%     | SMD = 0.921 (0.499–1.343) | Z = 4.28 P < 0.001 | T = 1.52 P = 0.166 | [27, 28, 32, 36, 37, 41, 44, 46, 49] |
| CSF      | MS      | IND/NIND | 11               | 1081/712             | (χ² = 98.67, P < 0.001) | I² = 89.9%     | SMD = 0.699 (0.296–1.103) | Z = 3.40 P < 0.001 | T = 2.43 P = 0.038 | [27–29, 32, 35–37, 41, 45, 46, 49] |
| CSF      | MS      | IND/NIND and HC | 12          | 1167/764            | (χ² = 100.02, P < 0.001) | I² = 89.0%     | SMD = 0.645 (0.285–1.006) | Z = 3.51 P < 0.001 | T = 2.37 P = 0.039 | [27–29, 32, 35–37, 41, 44, 46, 49] |
| CSF      | MS (untreated) | NIND | 5                 | 293/132              | (χ² = 4.05, P = 0.400) | I² = 1.2%      | SMD = 0.705 (0.485–0.924) | Z = 6.29 P < 0.001 | T = 1.68 P = 0.191 | [27, 28, 36, 41, 46] |
| CSF      | MS (untreated) | NIND and HC | 6               | 379/171             | (χ² = 7.35, P = 0.196) | I² = 32.0%     | SMD = 0.603 (0.413–0.793) | Z = 6.22 P < 0.001 | T = 2.35 P = 0.079 | [27, 28, 36, 41, 46] |
| CSF      | MS (untreated) | IND/NIND | 5                | 293/143             | (χ² = 8.05, P = 0.090) | I² = 50.3%     | SMD = 0.612 (0.297–0.926) | Z = 3.82 P < 0.001 | T = 0.72 P = 0.522 | [27, 28, 36, 41, 46] |
| CSF      | MS (untreated) | IND/NIND and HC | 6           | 379/182            | (χ² = 9.78, P = 0.082) | I² = 48.9%     | SMD = 0.545 (0.276–0.814) | Z = 3.97 P < 0.001 | T = 1.15 P = 0.314 | [27, 28, 36, 41, 44, 46] |
| CSF      | CIS     | NIND and HC | 4                | 243/305            | (χ² = 1.79, P = 0.618) | I² = 0.0%      | SMD = 0.199 (0.029–0.369) | Z = 2.30 P = 0.022 | N/A         | [27, 37, 44, 46] |
| CSF      | RRMS    | NIND     | 6                 | 551/359             | (χ² = 42.20, P < 0.001) | I² = 88.2%     | SMD = 1.124 (0.590–1.658) | Z = 4.13 P < 0.001 | T = 1.42 P = 0.229 | [27, 36, 37, 41, 46] |
| CSF      | RRMS    | NIND and HC | 7               | 595/398            | (χ² = 49.26, P < 0.001) | I² = 87.8%     | SMD = 0.989 (0.516–1.463) | Z = 4.09 P < 0.001 | T = 1.08 P = 0.328 | [27, 36, 37, 41, 44, 46] |
| CSF      | RRMS (untreated) | NIND and HC | 5              | 155/147            | (χ² = 10.41, P = 0.034) | I² = 61.6%     | SMD = 0.780 (0.387–1.173) | Z = 3.89 P < 0.001 | T = 1.13 P = 0.340 | [27, 36, 41, 44, 46] |
| CSF      | PPMS    | NIND     | 4                 | 68/286             | (χ² = 14.89, P = 0.002) | I² = 79.9%     | SMD = 1.183 (0.448–1.919) | Z = 3.15 P = 0.002 | N/A         | [27, 37, 41, 46] |
| CSF      | PPMS    | NIND and HC | 5               | 83/325             | (χ² = 15.43, P = 0.004) | I² = 74.1%     | SMD = 1.056 (0.494–1.619) | Z = 4.59 P < 0.001 | T = 3.05 P = 0.056 | [27, 37, 41, 44, 46] |
| CSF      | SPMS    | NIND     | 3                 | 122/267            | (χ² = 0.07, P = 0.968) | I² = 0.0%      | SMD = 0.586 (0.353–0.819) | Z = 4.93 P < 0.001 | N/A         | [27, 37, 41] |
| CSF      | Progressive MS | NIND     | 4                | 190/286           | (χ² = 2.44, P = 0.487) | I² = 0.0%      | SMD = 0.628 (0.426–0.826) | Z = 6.13 P < 0.001 | N/A | [27, 37, 41, 46] |
| CSF      | Progressive MS | NIND and HC | 5             | 205/325          | (χ² = 2.44, P = 0.655) | I² = 0.0%      | SMD = 0.882 (0.437–0.818) | Z = 6.47 P < 0.001 | N/A | [27, 37, 41, 44, 46] |
| CSF      | CIS     | RRMS     | 4                 | 243/488            | (χ² = 5.42, P = 0.143) | I² = 44.7%     | SMD = -0.360 (-0.639–0.081) | Z = 2.53 P = 0.011 | N/A | [27, 37, 44, 46] |
| CSF      | CIS     | PPMS     | 4                 | 243/62             | (χ² = 1.56, P = 0.669) | I² = 0.0%      | SMD = -0.435 (-0.723–0.046) | Z = 2.95 P = 0.003 | N/A | [27, 37, 44, 46] |
| CSF      | CIS     | Progressive MS | 4               | 243/144         | (χ² = 0.58, P = 0.900) | I² = 0.0%      | SMD = -0.421 (-0.634–0.208) | Z = 3.87 P < 0.001 | N/A | [27, 37, 44, 46] |

(Continued)
proposed to be consequent to enhanced survival of autoreactive T cells mediated by OPN [19]. New evidence suggests that OPN can increase IL-17 production and thereby lead to Th17 differentiation, which is another T cell activation pathway that may induce autoimmunity in MS [55, 58–60].

While OPN levels are significantly higher in CSF of MS patients compared to non-inflammatory controls, we did not detect any significant difference between MS patients and patients with other inflammatory neurological disorders regarding their CSF concentration of OPN. Therefore, we can conclude that presence of any inflammatory process within CNS may lead to increased level of OPN in CSF.

In the present study, we also compared the CSF and peripheral blood levels of OPN among the subtypes of MS patients. The result demonstrates lower CSF and peripheral blood levels of OPN in CIS patients compared to patients with progressive subtypes of MS. This finding supports the possibility for coexistence of neurodegeneration and neuroinflammation in progressive MS [1]. Higher CSF and blood levels of OPN have also been found in common neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease; however, high OPN levels cannot be the sole culprit because evidence regarding the neuroprotective effects of OPN also exist [61–63]. We have also shown that CSF concentration of OPN is greater among RRMS patients compared to CIS and SPMS patients. Furthermore, concentrations of OPN in CSF of patients with active MS are significantly increased compared to patients with stable disease. These findings suggest that higher levels of OPN are associated with more active inflammation and highlight the potential of OPN as a prognostic biomarker for patients diagnosed with MS.

In the present meta-analysis, we found a high rate of between-study heterogeneity. The difference in design and sample processing methods of the included studies might be the main cause of this heterogeneity [11]. Sample collection methodology is especially important in peripheral blood biomarker assays because either serum or plasma with different procedures can be used. Although plasma samples are obtained more easily, serum samples are preferred for biomarker detection because of their higher sensitivity [64]. As was mentioned above, differences in study designs are another potential cause of inconsistency among the studies. However, we should not forget that MS is naturally a heterogeneous disease with different subtypes.

**Table 2.** (Continued)

| Specimen | Group I | Group II | No of comparisons | Heterogeneity | Inconsistency | Effect measure (95% CI) | Overall effect (p value) | Egger’s test | References |
|----------|---------|----------|-------------------|---------------|---------------|------------------------|--------------------------|-------------|------------|
| CSF      | RRMS    | PPMS     | 5 524/83          | $X^2 = 6.41$  | $I^2 = 37.6\%$ | SMD = 0.088 (-0.158–0.334) | Z = 0.70 P = 0.485          | T = -1.42 P = 0.252 | [27, 37, 41, 44, 46] |
| CSF      | RRMS    | SPMS     | 3 463/96          | $X^2 = 2.39$  | $I^2 = 16.2\%$ | SMD = 0.342 (0.089–0.595) | Z = 2.65 P = 0.008          | N/A         | [27, 37, 41] |
| CSF      | RRMS    | Progressive MS | 5 524/205      | $X^2 = 8.88$  | $I^2 = 55.0\%$ | SMD = 0.142 (-0.158–0.443) | Z = 0.93 P = 0.353          | T = -0.77 P = 0.497 | [27, 37, 41, 44, 46] |
| CSF      | SPMS    | PPMS     | 3 96/58           | $X^2 = 4.95$  | $I^2 = 59.6\%$ | SMD = -0.227 (-0.771–0.318) | Z = 0.82 P = 0.414          | N/A         | [27, 37, 41] |
| CSF      | Active MS | Stable MS | 3 103/333         | $X^2 = 3.14$  | $I^2 = 36.3\%$ | SMD = 0.323 (0.090–0.556) | Z = 2.71 P = 0.007          | N/A         | [29, 37, 46] |

*patients who were drug naïve or samples were collected after the washout period.

https://doi.org/10.1371/journal.pone.0190252.t002
Table 3. Summary of meta-analyses undertaken in studies which measured peripheral blood levels of OPN.

| Specimen        | Group I | Group II | No of comparisons | No of group 1/ group 2 | Heterogeneity chi² | Inconsistency | Effect measure (95% CI) | Overall effect (p value) | Egger’s test | References |
|-----------------|---------|----------|-------------------|------------------------|--------------------|---------------|------------------------|--------------------------|--------------|------------|
| Plasma          | MS      | HC       | 6                 | 760/138                | $X^2 = 7.55$               | $P = 0.183$ | $I^2 = 33.7$%          | $Z = 4.97$               | $T = 3.30$ | [20, 27, 33, 38, 48] |
| Serum           | MS      | HC       | 4                 | 202/168                | $X^2 = 10.67$             | $P = 0.014$ | $I^2 = 71.9$%          | $Z = 4.09$               | $T = 0.014$| [22, 26, 39, 44]  |
| Serum/Plasma    | MS      | HC       | 10                | 962/306                | $X^2 = 24.79$             | $P = 0.003$ | $I^2 = 63.7$%          | $Z = 5.47$               | $T = 2.16$ | [20, 22, 26, 27, 33, 34, 38, 39, 44, 48] |
| Plasma (untreated) | HC     | 4        | 256/109           | 584/138                | $X^2 = 5.13$              | $P = 0.163$ | $I^2 = 41.5$%          | $Z = 3.52$               | $T = 0.014$| [27, 33, 34, 38]  |
| Serum (untreated) | HC     | 6        | 352/158           | 8.89                   | $X^2 = 43.8$              | $P = 0.013$ | $I^2 = 33.7$%          | $Z = 4.22$               | $T = 3.40$ | [27, 33, 34, 39, 44] |
| Serum/Plasma    | MS      | NIND     | 3                 | 175/116                | $X^2 = 4.75$              | $P = 0.093$ | $I^2 = 57.9$%          | $Z = 0.37$               | $T = 0.014$| [27, 28, 49]  |
| Plasma          | MS      | NIND and HC | 7               | 787/206                | $X^2 = 14.40$             | $P = 0.025$ | $I^2 = 58.3$%          | $Z = 2.98$               | $T = 2.13$ | [20, 27, 28, 33, 34, 38, 48] |
| Serum           | MS      | NIND and HC | 5               | 253/216                | $X^2 = 15.11$             | $P = 0.004$ | $I^2 = 73.5$%          | $Z = 4.00$               | $T = 0.014$| [22, 26, 39, 44, 49] |
| Serum/Plasma    | MS      | NIND and HC | 12              | 1040/422               | $X^2 = 43.3$              | $P < 0.001$ | $I^2 = 74.6$%          | $Z = 4.47$               | $T = 2.1$  | [20, 22, 26–28, 33, 34, 38, 39, 44, 48] |
| Serum/Plasma    | MS (Stable) | NIND and HC | 5              | 131/123                | $X^2 = 11.59$             | $P = 0.021$ | $I^2 = 65.9$%          | $Z = 2.86$               | $T = 1.92$ | [28, 33, 34, 43, 49] |
| Serum/Plasma    | MS (untreated) | NIND and HC | 7              | 330/237                | $X^2 = 22.75$             | $P = 0.001$ | $I^2 = 73.6$%          | $Z = 2.76$               | $T = 2.46$ | [27, 28, 33, 34, 39, 44] |
| Serum/Plasma    | MS      | IND/NIND  | 3                 | 175/127                | $X^2 = 4.78$              | $P = 0.092$ | $I^2 = 58.1$%          | $Z = 0.35$               | $T = 0.014$| [27, 28, 49]  |
| Serum/Plasma    | MS      | IND/NIND and HC | 12          | 1040/433               | $X^2 = 44.08$             | $P < 0.001$ | $I^2 = 53.0$%          | $Z = 4.44$               | $T = 2.16$ | [20, 22, 26–28, 33, 34, 38, 39, 44, 48] |
| Serum/Plasma    | MS (stable) | IND/NIND and HC | 5          | 180/134                | $X^2 = 12.22$             | $P = 0.016$ | $I^2 = 67.3$%          | $Z = 2.81$               | $T = 0.25$ | [28, 33, 34, 43, 49] |
| Serum/Plasma    | MS (untreated) | IND/NIND and HC | 7          | 330/237                | $X^2 = 22.75$             | $P < 0.001$ | $I^2 = 73.6$%          | $Z = 2.76$               | $T = 2.46$ | [27, 28, 33, 34, 39, 44] |
| Serum/Plasma    | CIS     | HC       | 3                 | 77/127                 | $X^2 = 3.94$              | $P = 0.139$ | $I^2 = 49.3$%          | $Z = 1.64$               | $T = 0.102$| [27, 28, 44] |
| Serum/Plasma    | CIS     | NIND and HC | 3              | 77/161                 | $X^2 = 5.83$              | $P = 0.054$ | $I^2 = 65.7$%          | $Z = 1.01$               | $T = 0.102$| [27, 28, 44] |
| Plasma          | RRMS    | HC       | 7                 | 588/158                | $X^2 = 18.59$             | $P < 0.001$ | $I^2 = 67.7$%          | $Z = 3.30$               | $T = 1.84$ | [20, 27, 33, 34, 38, 43, 48] |
| Serum           | RRMS    | HC       | 3                 | 89/87                  | $X^2 = 15.60$             | $P < 0.001$ | $I^2 = 87.2$%          | $Z = 2.01$               | $T = 0.045$| [26, 39, 44] |
| Serum/Plasma    | RRMS    | HC       | 10                | 677/245                | $X^2 = 36.59$             | $P < 0.001$ | $I^2 = 75.4$%          | $Z = 4.07$               | $T = 0.064$| [20, 26, 27, 33, 34, 38, 39, 43, 44, 48] |
| Plasma          | RRMS (remission) | HC | 7             | 588/158                | $X^2 = 18.59$             | $P < 0.001$ | $I^2 = 67.7$%          | $Z = 3.30$               | $T = 1.84$ | [20, 27, 33, 34, 38, 43, 48] |
| Plasma          | RRMS (untreated) | HC | 4             | 197/109                | $X^2 = 10.86$             | $P = 0.013$ | $I^2 = 72.4$%          | $Z = 2.07$               | $T = 0.038$| [27, 33, 34, 38] |

(Continued)
Table 3. (Continued)

| Specimen | Group I | Group II | No of comparisons | No of group 1 vs group 2 | Heterogeneity $\chi^2$ | Inconsistency | Effect measure (95% CI) | Overall effect (p value) | Egger’s test | References |
|----------|---------|----------|-------------------|--------------------------|------------------------|---------------|--------------------------|--------------------------|-------------|------------|
| Serum/Plasma | RRMS (untreated$^*$) | HC | 6 | 251/158 | $\chi^2 = 16.35$ | $I^2 = 69.4\%$ | SMD = 0.555 (0.147–0.964) | $Z = 2.66$ | $P = 0.008$ | T = 1.40 | $P = 0.234$ | [27, 33, 34, 38, 39, 44] |
| Plasma | RRMS | NIND and HC | 7 | 588/202 | $\chi^2 = 27.22$ | $I^2 = 78.0\%$ | SMD = 0.618 (0.186–1.050) | $Z = 2.81$ | $P = 0.005$ | T = 2.01 | $P = 0.101$ | [20, 27, 33, 34, 38, 43, 48] |
| Serum | RRMS | NIND and HC | 4 | 140/135 | $\chi^2 = 17.71$ | $I^2 = 83.1\%$ | SMD = 0.808 (0.164–1.451) | $Z = 2.46$ | $P = 0.014$ | N/A | [26, 39, 44, 49] |
| Serum/Plasma | RRMS | NIND and HC | 11 | 728/337 | $\chi^2 = 47.10$ | $I^2 = 78.8\%$ | SMD = 0.682 (0.340–1.024) | $Z = 3.90$ | $P < 0.001$ | T = 2.56 | $P = 0.031$ | [20, 26, 27, 33, 34, 38, 39, 43, 44, 48, 49] |
| Serum/Plasma | RRMS (remission) | NIND and HC | 3 | 87/79 | $\chi^2 = 4.49$ | $I^2 = 55.5\%$ | SMD = 0.736 (0.198–1.274) | $Z = 2.68$ | $P = 0.007$ | N/A | [27, 33, 34, 38, 39, 44] |
| Serum/Plasma | RRMS (untreated$^*$) | NIND and HC | 6 | 251/202 | $\chi^2 = 24.20$ | $I^2 = 79.3\%$ | SMD = 0.540 (0.069–1.012) | $Z = 2.25$ | $P = 0.025$ | T = 1.73 | $P = 0.325$ | [33, 34, 49] |
| Plasma | SPMS | HC | 4 | 96/108 | $\chi^2 = 12.40$ | $I^2 = 75.8\%$ | SMD = 0.879 (0.186–1.572) | $Z = 2.49$ | $P = 0.013$ | N/A | [20, 27, 38, 43] |
| Plasma | SPMS | NIND and HC | 4 | 96/152 | $\chi^2 = 10.71$ | $I^2 = 72.0\%$ | SMD = 0.646 (0.058–1.234) | $Z = 2.15$ | $P = 0.031$ | N/A | [20, 27, 38, 43] |
| Plasma | PPMS | HC | 3 | 43/88 | $\chi^2 = 2.90$ | $I^2 = 31.1\%$ | SMD = 0.798 (0.412–1.183) | $Z = 4.06$ | $P < 0.001$ | N/A | [20, 27, 38] |
| Serum/Plasma | PPMS | HC | 4 | 58/127 | $\chi^2 = 3.47$ | $I^2 = 13.5\%$ | SMD = 0.875 (0.546–1.203) | $Z = 5.21$ | $P < 0.001$ | N/A | [20, 27, 38, 44] |
| Plasma | PPMS | NIND and HC | 3 | 43/132 | $\chi^2 = 0.08$ | $I^2 = 0.0\%$ | SMD = 0.660 (0.291–1.028) | $Z = 3.51$ | $P < 0.001$ | N/A | [20, 27, 38] |
| Serum/Plasma | PPMS | NIND and HC | 4 | 58/171 | $\chi^2 = 1.36$ | $I^2 = 0.0\%$ | SMD = 0.767 (0.448–1.085) | $Z = 4.72$ | $P < 0.001$ | N/A | [20, 27, 38, 44] |
| Serum/Plasma | CIS | RRMS | 3 | 77/470 | $\chi^2 = 9.14$ | $I^2 = 78.1\%$ | SMD = 0.197 (-0.378–0.772) | $Z = 0.67$ | $P = 0.501$ | N/A | [27, 38, 44] |
| Serum/Plasma | CIS | PPMS | 3 | 77/48 | $\chi^2 = 1.70$ | $I^2 = 0.0\%$ | SMD = -0.088 (-0.858–0.714) | $Z = 2.56$ | $P = 0.010$ | N/A | [27, 38, 44] |
| Serum/Plasma | RRMS | PPMS | 5 | 533/63 | $\chi^2 = 21.95$ | $I^2 = 81.8\%$ | SMD = -0.436 (-1.131–0.259) | $Z = 1.23$ | $P = 0.219$ | T = -0.47 | $P = 0.672$ | [20, 25, 27, 38, 44] |
| Serum/Plasma | RRMS | SPMS | 5 | 500/108 | $\chi^2 = 43.922$ | $I^2 = 90.9\%$ | SMD = -0.495 (-1.400–0.409) | $Z = 1.07$ | $P = 0.283$ | T = -0.46 | $P = 0.674$ | [20, 25, 27, 38, 43] |
| Serum/Plasma | RRMS | Progressive MS | 6 | 544/171 | $\chi^2 = 45.83$ | $I^2 = 89.1\%$ | SMD = -0.546 (-1.371–0.118) | $Z = 1.61$ | $P = 0.107$ | T = -0.92 | $P = 0.408$ | [20, 25, 27, 38, 43, 44] |
| Serum/Plasma | PPMS | SPMS | 4 | 48/102 | $\chi^2 = 2.69$ | $I^2 = 0.0\%$ | SMD = 0.217 (-0.133–0.567) | $Z = 1.22$ | $P = 0.224$ | N/A | [20, 25, 27, 38] |

*patients who were drug naïve or samples were collected after the washout period.
†samples were collected during the remission period or after at least one month of stable disease in progressive types of MS.

https://doi.org/10.1371/journal.pone.0190252.1003

[65]. Even patients from the same category of the disease are not essentially similar to each other due to incongruity of their disease course [65]. Thus, part of this heterogeneity is inevitable and
Fig 2. CSF concentration of OPN in MS patients compared to controls. (A) MS patients compared to all controls. (B) CIS patients compared to HCs and NIND patients. (C) RRMS patients compared to HCs and NIND patients. (D) PPMS patients compared to HCs and NIND patients. (E) SPMS patients compared to NIND patients.

https://doi.org/10.1371/journal.pone.0190252.g002
Fig 3. Meta-analysis of peripheral blood OPN levels: MS patients compared to controls. (A) MS patients versus all controls. (B) CIS patients versus HCs. (C) RRMS patients versus HCs and NIND patients. (D) PPMS patients versus HCs and NIND patients. (E) SPMS patients versus HCs and NIND patients.

https://doi.org/10.1371/journal.pone.0190252.g003
Fig 4. CSF and peripheral blood concentration of OPN; comparisons among subtypes of MS. (A) CIS vs RRMS (first CSF, second peripheral blood). (B) CIS vs PPMS (first CSF, second peripheral blood). (C) RRMS vs SPMS (first CSF, second peripheral blood). (D) SPMS vs PPMS (first CSF, second peripheral blood). (E) Active MS vs Stable MS (only CSF).

https://doi.org/10.1371/journal.pone.0190252.g004
could be a reflection of diversity among patients in their disease activity status; therefore, this might manifest OPN strength in defining the true nature of the disease. The dissimilarity between studies in their control groups, treatment status, and disease activity status are among important sources of heterogeneity, which we tried to attenuate by subgroup analyses [11].

The present study is the first systematic review and meta-analysis of studies which measured peripheral blood and CSF levels of OPN in MS patients and controls. However, we should mention some limitations. Although the existing data strongly suggest that higher levels of OPN are present in peripheral blood and CSF of MS patients compared to the controls, very limited studies were included in most of the subgroup analyses; so to achieve more reliable results, we need more studies to be included in these subgroups. Considerable heterogeneity among the included studies, which we discussed earlier, is another limitation of the present study. Finally, publication bias is a challenging issue in biomarker studies which may affect results of meta-analyses and their reliability [66]. We found publication bias in few meta-analyses of peripheral blood and CSF studies.

In conclusion, the result of this study confirms that increased levels of OPN exist in CSF and peripheral blood of MS patients and strengthens the evidence regarding the clinical utility of OPN as a promising and validated biomarker for MS. In our opinion, OPN can be applied as diagnostic or predictive, and prognostic biomarker in the clinical setting. An elevated level of OPN in a patient at risk of MS may be suggestive of active inflammation. Given the fact that OPN levels are higher during relapses, we think that by monitoring this biomarker we might be able to predict the disease course. Finally, we propose that developing drugs modulating OPN concentration may be a new treatment strategy for MS.

Supporting information

S1 File. PRISMA 2009 checklist.
(DOC)

S2 File. Funnel plots for CSF studies.
(DOCX)

S3 File. Funnel plots for peripheral blood studies.
(DOCX)

S1 Appendix. Search strategy.
(DOCX)

S1 Table. Main characteristics of the included studies.
(DOCX)

Acknowledgments

We thank all colleagues who provided us with the information we needed for this study.

Author Contributions

Conceptualization: Elmira Agah, Arshia Zardoui, Amene Saghazadeh, Abbas Tafakhori, Nima Rezaei.

Data curation: Elmira Agah, Arshia Zardoui, Amene Saghazadeh, Abbas Tafakhori, Nima Rezaei.

Formal analysis: Elmira Agah, Amene Saghazadeh.
Investigation: Elmira Agah, Arshia Zardoui, Abbas Tafakhori.

Methodology: Elmira Agah, Abbas Tafakhori, Nima Rezaei.

Project administration: Elmira Agah.

Resources: Elmira Agah, Arshia Zardoui.

Software: Elmira Agah, Arshia Zardoui.

Supervision: Elmira Agah, Mona Ahmadi, Abbas Tafakhori, Nima Rezaei.

Writing – original draft: Elmira Agah, Arshia Zardoui.

Writing – review & editing: Amene Saghazadeh, Mona Ahmadi, Abbas Tafakhori, Nima Rezaei.

References

1. Hemmer B, Kerschensteiner M, Kom T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. The Lancet Neurology. 2015; 14(4):406–19. Epub 2015/03/21. https://doi.org/10.1016/S1474-4422(14)70305-9 PMID: 25792099.

2. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. The American journal of managed care. 2013; 19(2 Suppl):S15–20. Epub 2013/04/12. PMID: 23544716.

3. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014; 83(3):278–86. https://doi.org/10.1212/WNL.0000000000000560 PMC4117366. PMID: 24871874.

4. Chung S-E, Cheong H-K, Park J-H, Kim HJ. Burden of Disease of Multiple Sclerosis in Korea. Epidemiology and Health. 2012; 34:e2012008. https://doi.org/10.4178/epih/e2012008 PMC3521103. PMID: 23251838.

5. Teunissen CE, Malekzadeh A, Leurs C, Bridel C, Killestein J. Body fluid biomarkers for multiple sclerosis—the long road to clinical application. Nature reviews Neurology. 2015; 11(10):585–96. Epub 2015/09/24. https://doi.org/10.1038/nrneurol.2015.173 PMID: 26392381.

6. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011; 69(2):292–302. Epub 2011/03/10. https://doi.org/10.1002/ana.22366 PMID: 21387374; PubMed Central PMCID: PMCPmc3984507.

7. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. The Lancet Neurology. 2016; 15(3):292–303. Epub 2016/01/30. https://doi.org/10.1016/S1474-4222(15)00393-2 PMID: 26822746; PubMed Central PMCID: PMCPmc4760851.

8. Kanekar S, Devgun P. A pattern approach to focal white matter hyperintensities on magnetic resonance imaging. Radiologic clinics of North America. 2014; 52(2):241–61. Epub 2014/03/04. https://doi.org/10.1016/j.rcl.2013.11.010 PMID: 24582339.

9. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Archives of neurology. 2005; 62(6):865–70. Epub 2005/06/16. https://doi.org/10.1001/archneur.62.6.865 PMID: 1596157.

10. Giessner BS. Diagnosis of multiple sclerosis. Neurologic clinics. 2011; 29(2):381–8. Epub 2011/03/29. https://doi.org/10.1016/j.ncl.2010.12.001 PMID: 21439447.

11. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. The Lancet Neurology. 2014; 13(1):113–26. Epub 2013/12/18. https://doi.org/10.1016/S1474-4422(13)70233-3 PMID: 24331797.

12. Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clinical immunology (Orlando, Fla). 2015; 161(1):51–8. Epub 2015/07/06. https://doi.org/10.1016/j.clim.2015.06.015 PMID: 26143623.

13. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology and therapeutics. 2001; 69(3):89–95. Epub 2001/03/10. https://doi.org/10.1007/113989 PMID: 11240971.

14. Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Molecular diagnosis & therapy. 2014; 18(6):605–17. Epub 2014/08/29. https://doi.org/10.1007/s40291-014-0117-6 PMID: 25164543; PubMed Central PMCID: PMCPmc4245485.
15. Bandopadhayay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, et al. Osteopontin as a therapeutic target for cancer. Expert opinion on therapeutic targets. 2014; 18(8):883–95. Epub 2014/06/06. https://doi.org/10.1517/14728222.2014.925447 PMID: 24899149.

16. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory signaling. Journal of cell communication and signaling. 2009; 3(3–4):311–22. Epub 2009/10/03. https://doi.org/10.1007/s12079-009-0068-0 PMID: 19798593; PubMed Central PMCID: PMCPmc2778587.

17. Rittling SR, Singh R. Osteopontin in Immune-mediated Diseases. Journal of dental research. 2015; 94(12):1638–45. Epub 2015/09/06. https://doi.org/10.1177/0022034515605270 PMID: 26341976; PubMed Central PMCID: PMCPmc4681477.

18. Chabas DE, Steinman L, Rittling SR, Sobel R, Lock C, Mitchell D, et al. Elevated osteopontin transcripts in MS brain libraries and its role in the development of progressive versus remitting autoimmune encephalomyelitis. Faseb Journal. 2001; 15(4):A354–A. WOS:000067438102025.

19. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature immunology. 2007; 8(1):74–83. Epub 2006/12/05. https://doi.org/10.1038/nii1415 PMID: 17143274.

20. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Annals of neurology. 2003; 53(6):819–22. Epub 2003/06/05. https://doi.org/10.1002/ana.10606 PMID: 12783433.

21. Bornsen L, Khandemi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2011; 17(1):32–42. Epub 2010/10/06. https://doi.org/10.1177/1352458810382247 PMID: 20921238.

22. Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? Journal of the neurological sciences. 2009; 276(1–2):41–4. Epub 2008/10/11. https://doi.org/10.1016/j.jns.2008.08.031 PMID: 18845306.

23. Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A, et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PloS one. 2011; 6(9):e24240. Epub 2011/09/22. https://doi.org/10.1371/journal.pone.0024240 PMID: 21935858; PubMed Central PMCID: PMCPmc3174149.

24. Vogt MH, Floris S, Kilistein J, Knol DL, Smits M, Barkhof F, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. Journal of neuroimmunology. 2004; 153(1–2):155–60. Epub 2004/09/03. https://doi.org/10.1016/j.jneuroim.2004.06.007 PMID: 15342207.

25. Alattins A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? Journal of the neurological sciences. 2009; 276(1–2):41–4. Epub 2008/10/11. https://doi.org/10.1016/j.jns.2008.08.031 PMID: 18845306.

26. Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A, et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PloS one. 2011; 6(9):e24240. Epub 2011/09/22. https://doi.org/10.1371/journal.pone.0024240 PMID: 21935858; PubMed Central PMCID: PMCPmc3174149.

27. Bornsen L, Khandemi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2011; 17(1):32–42. Epub 2010/10/06. https://doi.org/10.1177/1352458810382247 PMID: 20921238.

28. Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Archives of neurology. 2008; 65(5):633–5. Epub 2008/05/14. https://doi.org/10.1001/archneur.65.5.633 PMID: 18447739.

29. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Archives of neurology. 2008; 65(2):232–5. Epub 2008/02/13. https://doi.org/10.1001/archneur.2007.33 PMID: 18268193.

30. Comabella M, Pericot I, Goertches R, Nos C, Castillo M, Blas Navarro J, et al. Plasma osteopontin levels in multiple sclerosis. Journal of neuroimmunology. 2005; 158(1–2):231–9. Epub 2004/12/14. https://doi.org/10.1016/j.jneuroim.2004.09.004 PMID: 15689058.

31. Comi C, Cappellano G, Chiocchetti A, Orili E, Buttini S, Ghezzi L, et al. The impact of osteopontin gene variations on multiple sclerosis development and progression. Clinical & developmental immunology. 2012; 2012:212893. Epub 2012/09/26. https://doi.org/10.1155/2012/212893 PMID: 23008732; PubMed Central PMCID: PMCPmc3447190.

32. Edwards LJ, Sharrack B, Ismail A, Tench CR, Gran B, Dhungana S, et al. Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. American journal of clinical and experimental immunology. 2013; 2(3):234–44. Epub 2013/11/02. PMID: 24179731; PubMed Central PMCID: PMCPmc3808932.
33. Ferret-Sena V, Maia ESA, Sena A. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. 2016; 2016:5716415. https://doi.org/10.1155/2016/5716415 PMID: 28077943.

34. Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain, behavior, and immunity. 2014; 35:176–81. Epub 2013/09/03. https://doi.org/10.1016/bbi.2013.08.009 PMID: 23994630.

35. Kariya Y, Kariya Y, Saito T, Nishiyama S, Honda T, Tanaka K, et al. Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. BBA clinical. 2015; 3:126–34. Epub 2015/12/18. https://doi.org/10.1016/j.bbacci.2015.01.003 PMID: 26673877; PubMed Central PMCID: PMCPmc4661545.

36. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. European journal of neurology. 2009; 16(4):528–36. Epub 2009/02/18. https://doi.org/10.1111/j.1468-1331.2009.02532.x PMID: 19220425.

37. Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer F, Harris RA, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PloS one. 2013; 8(6):e63172. Epub 2013/05/15. https://doi.org/10.1371/journal.pone.0063172 PMID: 23667585; PubMed Central PMCID: PMCPmc3646751.

38. Kivisakk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple sclerosis (Houndmills, Basingstoke, England). 2014; 20(4):438–44. Epub 2013/09/06. https://doi.org/10.1177/1352458513503052 PMID: 24005206.

39. Ma N, He Y, Xiao H, Han G, Chen G, Wang Y, et al. BAFF maintains T-cell survival by inducing OPN expression in B cells. Molecular immunology. 2014; 57(2):129–37. Epub 2013/10/03. https://doi.org/10.1016/j.molimm.2013.08.014 PMID: 24084099.

40. Ratzer R, Iversen P, Bornsen L, Dyrbys TB, Romme Christensen J, Ammitzboll C, et al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2015. Epub 2015/10/04. https://doi.org/10.1177/1352458515605908 PMID: 26432857.

41. Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2013; 19(7):877–84. Epub 2012/11/28. https://doi.org/10.1177/1352458512466929 PMID: 23178691.

42. Romme Christensen J, Ratzer R, Bornsen L, Lyksborg M, Garde E, Dyrbys TB, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014; 82(17):1499–507. Epub 2014/04/01. https://doi.org/10.1212/WNL.000000000000361 PMID: 24682973.

43. Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C, Uchiyama S. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. Journal of neuroimmunology. 2013; 263(1–2):148–51. Epub 2013/08/06. https://doi.org/10.1016/j.jneuroim.2013.07.005 PMID: 23910387.

44. Stilund M, Gjelstrup MC, Petersen T, Moller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PloS one. 2015; 10(4):e0119681. Epub 2015/04/11. https://doi.org/10.1371/journal.pone.0119681 PMID: 25860354; PubMed Central PMCID: PMCPmc4393241.

45. Strehlow F, Bauer S, Martus P, Weller M, Roth P, Schlegel U, et al. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. 2016; 129(1):165–71. https://doi.org/10.1007/s10380-016-2162-5 PMID: 27294357.

46. Szalardy L, Zadori D, Sirmu M, Bencsik K, Vecsei L, Klivenyi P. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Journal of the neurological sciences. 2013; 331(1–2):38–42. Epub 2013/05/28. https://doi.org/10.1016/j.jns.2013.04.024 PMID: 23706476.

47. Tumani H, Kasubek J, Hlijazi M, Lehmensiek V, Unrath A, Sussmuth S, et al. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. European neurology. 2011; 65(3):164–9. Epub 2011/03/05. https://doi.org/10.1159/000324036 PMID: 21372576.

48. Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Multiple sclerosis (Houndmills, Basingstoke, England). 2010; 16(4):443–9. Epub 2010/01/21. https://doi.org/10.1177/1352458509359723 PMID: 20086024.
49. Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of neuroimmunology. 2012; 244(1–2):94–6. Epub 2012/02/15. https://doi.org/10.1016/j.jneuroim.2011.12.004 PMID: 22329905.

50. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009; 339:b2535. Epub 2009/07/23. https://doi.org/10.1136/bmj.b2535 PMID: 19622551; PubMed Central PMCID: PMCPmc2714657.

51. Wells GA, Shea B, O'connell D, Peterson JE, Welch V, Losos M, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.

52. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2011.

53. Egger M,Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315(7109):629–34. Epub 1997/10/06. PMID: 9310563; PubMed Central PMCID: PMCPmc2127453.

54. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Archives of neurology. 2004; 61(10):1613–5. Epub 2004/10/13. https://doi.org/10.1001/archneur.61.10.1613 PMID: 15477521.

55. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. Journal of immunology (Baltimore, Md: 1950). 2008; 181(11):7480–8. Epub 2008/11/20. PMID: 19107937; PubMed Central PMCID: PMCPmc2653058.

56. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. The Journal of clinical investigation. 2001; 107(9):1055–61. Epub 2001/05/09. https://doi.org/10.1172/JCI12980 PMID: 11342566; PubMed Central PMCID: PMCPmc209291.

57. Kawamura K, Iyonaga K, Ichiyasu H, Nagano J, Suga M, Sasaki Y. Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clinical and diagnostic laboratory immunology. 2005; 12(1):206–12. Epub 2005/01/12. https://doi.org/10.1128/CDLI.12.1.206-212.2005 PMID: 15643009; PubMed Central PMCID: PMCPmc540203.

58. Diao H, Liu X, Wu Z, Kang L, Cui G, Morimoto J, et al. Osteopontin regulates interleukin-17 production in hepatitis. Cytokine. 2012; 60(1):129–37. Epub 2012/07/24. https://doi.org/10.1016/j.cyto.2012.06.287 PMID: 22818182.

59. Han RK, Cheng YF, Zhou SS, Guo H, He RD, Chi LJ, et al. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barre syndrome. Journal of clinical immunology. 2013; 34(1):94–103. Epub 2013/11/13. https://doi.org/10.1007/s10875-013-9965-3 PMID: 24217817.

60. Jones AP, Kermode AG, Lucas RM, Nolan D, Hart PH. Circulating immune cells in multiple sclerosis. Clinical and experimental immunology. 2017; 187(2):193–203. Epub 2016/11/03. https://doi.org/10.1111/cei.12878 PMID: 27689339; PubMed Central PMCID: PMCPmc5217866.

61. Careccio M, Cori C. The role of osteopontin in neurodegenerative diseases. Journal of Alzheimer’s disease: JAD. 2011; 25(2):179–85. Epub 2011/03/02. https://doi.org/10.3233/JAD-2011-102151 PMID: 21358042.

62. Corni C, Careccio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer’s disease and its levels correlate with cognitive decline. Journal of Alzheimer’s disease: JAD. 2010; 19(4):1143–8. Epub 2010/03/24. https://doi.org/10.3233/JAD-2010-1309 PMID: 20308780.

63. Sun Y, Yin XS, Guo H, Han RK, He RD, Chi LJ. Elevated osteopontin levels in mild cognitive impairment and Alzheimer’s disease. Mediators of inflammation. 2013; 2013:615745. Epub 2013/04/12. https://doi.org/10.1155/2013/615745 PMID: 23576854; PubMed Central PMCID: PMCPmc3612435.

64. Yu Z, Kastenmüller G, He Y, Belcredi P, Moller G, Prehn C, et al. Differences between human plasma and serum metabolite profiles. PloS one. 2011; 6(7):e21230. Epub 2011/07/16. https://doi.org/10.1371/journal.pone.0021230 PMID: 21760889; PubMed Central PMCID: PMCPmc3132215.

65. Dendrou CA, Fugger L, Fries MA. Immunopathology of multiple sclerosis. Nature reviews Immunology. 2015; 15(9):545–58. Epub 2015/08/08. https://doi.org/10.1038/nri3871 PMID: 26250739.

66. Carvalho AF, Kohler CA, Brunoni AR, Miskowiak KW, Herrmann N, Lancot KL, et al. Bias in Peripheral Depression Biomarkers. Psychotherapy and psychosomatics. 2016; 85(2):81–90. Epub 2016/01/26. https://doi.org/10.1159/000441457 PMID: 26806272.